Tag: Bavarian Nordic

WHO adds first mpox vaccine to prequalification list

by Emily Kimber | Sep 16, 2024 | News | 0

The decision is expected to facilitate timely access to Bavarian Nordic’s Imvanex

McMaster drug trial receives more than $6m to test smallpox vaccine against mpox

by Jen Brogan | Aug 15, 2024 | News | 0

Children accounted for the majority of mpox cases and deaths in the DRC since June 2023

Bavarian Nordic hit by cancer immunotherapy failure

by Selina McKee | Sep 18, 2017 | News | 0

Bavarian Nordic saw its shares plummet as much as 50 percent in the wake of news that the firm’s cancer immunotherapy ProstVac failed to prolong survival in men with a particular type of prostate cancer.

Bavarian Nordic, Roche to test bladder cancer combo

by Selina McKee | Mar 13, 2017 | News | 0

Roche and Bavarian Nordic have unveiled plans to assess the former’s anti-PD-L1 antibody Tecentriq in combination with the latter’s cancer vaccine candidate CV301 in bladder cancer.

BMS to supply Opdivo for Bavarian Nordic trial

by Selina McKee | Aug 16, 2016 | News | 0

Bristol-Myers Squibb has agreed to supply Bavarian Nordic with Opdivo for use in a clinical trial assessing the immunotherapy in combination with experimental drug CV301.